Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome
huh-red-i-tary fy-bro-sing poy-kil-o-der-ma ten-don con-trac-tures my-o-path-ee pul-muh-nair-ee fy-bro-sis sin-drome
Also known as: Poikiloderma with tendon contractures, Myopathy-pulmonary fibrosis syndrome
At a Glance
What is Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome?
Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome is a rare genetic disorder. It primarily affects the skin, muscles, tendons, and lungs. The condition is caused by mutations in specific genes that lead to abnormal connective tissue formation. Over time, individuals may experience worsening skin changes, muscle weakness, and breathing difficulties. Early symptoms often include skin discoloration and tendon stiffness, while later symptoms can involve significant muscle weakness and respiratory issues. Early diagnosis is crucial to manage symptoms and improve quality of life. This condition can have a profound impact on family life, requiring ongoing medical care and support. The prognosis varies, but early intervention can help manage symptoms effectively. Daily life for affected individuals may involve physical therapy and regular medical check-ups. Families may need to adapt their living environments to accommodate mobility challenges. Emotional and psychological support is also important for both patients and their families. Overall, the condition requires a multidisciplinary approach to care.
Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Poikiloderma manifests as a combination of skin changes including atrophy, telangiectasia, and pigmentation. It is caused by genetic mutations affecting skin structure and repair mechanisms. Over time, the skin may become more fragile and susceptible to damage. This condition can lead to significant cosmetic concerns and skin discomfort, and management includes sun protection and topical treatments.
Tendon contractures present as a restriction in joint movement due to the shortening of tendons. The underlying biological mechanism involves fibrotic changes in connective tissues. As the condition progresses, it can lead to joint stiffness and deformities. Daily life is affected by reduced mobility, and physical therapy along with surgical interventions can help manage the symptoms.
Myopathy is characterized by muscle weakness and fatigue. It results from genetic mutations affecting muscle fiber integrity and function. Over time, muscle weakness can progress, leading to difficulties in performing daily activities. Management includes physical therapy and supportive care to maintain muscle strength and function.
Common
Pulmonary fibrosis manifests as progressive scarring of lung tissue, leading to respiratory difficulties. The biological mechanism involves aberrant repair processes in the lung following injury. Over time, lung function declines, resulting in chronic cough and shortness of breath. Patients may require oxygen therapy and medications to slow disease progression.
Skin atrophy presents as thinning of the skin, making it more fragile and prone to injury. It is caused by a reduction in collagen and elastin production. As the condition progresses, the skin becomes increasingly delicate. Daily life can be affected by increased susceptibility to bruising and tears, and management includes protective measures and topical treatments.
Telangiectasia appears as small, visible blood vessels on the skin surface. It is caused by dilation of capillaries due to structural abnormalities. Over time, these lesions may increase in number and size. While primarily a cosmetic concern, laser therapy can be used to reduce their appearance.
Less Common
Hyperpigmentation is characterized by dark patches on the skin. It occurs due to an increase in melanin production in response to skin damage or inflammation. Over time, these patches may become more pronounced. Management involves the use of topical agents to lighten the skin and sun protection to prevent further darkening.
Joint stiffness is experienced as a reduced range of motion in the joints. It results from fibrotic changes in the connective tissues surrounding the joints. As the condition progresses, stiffness can become more pronounced, limiting daily activities. Physical therapy and exercises can help maintain joint flexibility and function.
What Causes Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome?
Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome is primarily caused by mutations in the FAM111B gene located on chromosome 11q12.1. The FAM111B gene encodes a protein involved in DNA replication and repair processes. Mutations in FAM111B lead to structural changes in the protein, impairing its ability to interact with DNA and other replication machinery. This disruption causes accumulation of DNA damage and genomic instability within the cell. As a result, cellular stress pathways are activated, leading to mitochondrial dysfunction and impaired energy metabolism. Neighboring cells and tissues experience increased oxidative stress and inflammation due to the release of pro-inflammatory cytokines. The immune response is further exacerbated by neuroinflammation, contributing to tissue degeneration. White matter degeneration occurs as a result of chronic inflammation and oxidative damage, affecting neural connectivity. Symptoms manifest in a specific pattern due to the differential vulnerability of tissues to oxidative stress and inflammation. Tendon contractures arise from fibrotic changes in connective tissues, while myopathy results from muscle fiber degeneration. Pulmonary fibrosis develops due to excessive deposition of extracellular matrix proteins in lung tissue. The variability in disease severity among patients is influenced by the specific mutation type, genetic background, and environmental factors. Some patients may exhibit more severe symptoms due to additional genetic variants that modulate the inflammatory response. Understanding the precise molecular mechanisms is crucial for developing targeted therapies. Further research is needed to explore potential interventions that can mitigate the effects of FAM111B mutations.
How is Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome Diagnosed?
Typical age of diagnosis: Diagnosis typically occurs in early childhood when symptoms such as skin changes, tendon contractures, and muscle weakness become apparent. Parents often notice these symptoms and seek medical evaluation. Early diagnosis is crucial for managing the condition effectively. Genetic counseling is recommended as part of the diagnostic process.
The clinician looks for characteristic skin changes such as poikiloderma, which includes mottled pigmentation, telangiectasia, and atrophy. A detailed family history is important to identify any hereditary patterns. Physical examination may reveal tendon contractures and muscle weakness. This step helps to narrow down the differential diagnosis and guides further testing.
High-resolution CT scans of the lungs are used to detect pulmonary fibrosis. Specific abnormalities such as reticular patterns and honeycombing are visible, which are indicative of fibrosis. These findings help confirm the diagnosis of pulmonary involvement in the syndrome. Imaging also helps exclude other conditions like emphysema or bronchiectasis.
Blood tests are ordered to assess muscle enzyme levels, such as creatine kinase, which may be elevated. Biomarkers like ANA or rheumatoid factor are checked to rule out autoimmune conditions. Abnormal results include elevated muscle enzymes and specific antibody profiles. These results guide the clinician to consider genetic testing as the next step.
Genes associated with hereditary fibrosing poikiloderma are sequenced, focusing on mutations in genes like FAM111B. Mutations typically include missense or nonsense mutations that affect protein function. Positive results confirm the diagnosis and provide a genetic basis for the condition. Genetic testing results are crucial for family counseling and assessing the risk in relatives.
Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome Treatment Options
Corticosteroids are used to manage inflammation and fibrosis. They work by suppressing the immune response and reducing inflammatory cytokine production. Specific drugs like prednisone are commonly used in clinical practice. Evidence for efficacy is based on case reports and small studies showing improvement in skin and pulmonary symptoms. Limitations include potential side effects like osteoporosis and immunosuppression.
Techniques such as stretching and strengthening exercises are employed. The goal is to maintain joint flexibility and muscle strength. Sessions are typically conducted 2-3 times a week, lasting about 30-60 minutes each. Measurable outcomes include improved range of motion and reduced contractures. Long-term benefits include enhanced mobility and quality of life.
Surgery is indicated for severe tendon contractures that limit function. The procedure involves releasing or lengthening the affected tendons. Expected benefits include improved joint mobility and pain relief. Surgical risks include infection, nerve damage, and recurrence of contractures. Post-operative care involves physical therapy to maintain surgical outcomes.
The care team includes dermatologists, pulmonologists, physical therapists, and genetic counselors. Interventions focus on managing symptoms, preventing complications, and providing psychosocial support. Strategies include regular follow-ups, counseling, and educational resources for families. Family education is crucial for understanding the condition and its management. Long-term monitoring includes regular assessments and adjustments to the care plan as needed.
When to See a Doctor for Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome
- Severe shortness of breath — this could indicate acute pulmonary complications requiring immediate medical attention.
- Sudden muscle weakness or paralysis — may suggest rapid progression of myopathy, necessitating urgent evaluation.
- Severe chest pain — could be a sign of pulmonary fibrosis exacerbation or other serious cardiac issues.
- Persistent cough — may indicate worsening pulmonary fibrosis and should be evaluated by a healthcare provider.
- Increasing joint stiffness — could suggest progression of tendon contractures, warranting a medical assessment.
- Fatigue that interferes with daily activities — may be a sign of systemic involvement and should be discussed with a doctor.
- Mild joint discomfort — monitor for any changes in severity or frequency and report to a healthcare provider if it worsens.
- Occasional shortness of breath during exertion — observe for any increase in frequency or severity and consult a doctor if it becomes more frequent.
Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome — Frequently Asked Questions
Is this condition hereditary?
Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome is inherited in an autosomal dominant pattern. This means there is a 50% chance of passing the condition to offspring if one parent is affected. De novo mutations can occur, meaning the condition can appear in individuals with no family history. Carrier status is not applicable as the condition is not recessive. Genetic counseling is recommended for affected individuals and their families to understand inheritance patterns and implications.
What is the life expectancy for someone with this condition?
Life expectancy can vary significantly depending on the age of onset and severity of symptoms. Early onset and severe pulmonary fibrosis are associated with a poorer prognosis. Respiratory failure due to pulmonary fibrosis is a common cause of mortality. Treatment can improve quality of life and potentially extend survival, but it is not curative. Realistic expectations should include managing symptoms and regular monitoring by healthcare professionals.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves a combination of clinical evaluation, genetic testing, and imaging studies. The time from first symptoms to diagnosis can vary, often taking several months due to the rarity of the condition. Specialists such as geneticists, pulmonologists, and neurologists are typically involved in the diagnostic process. Delayed diagnosis is common due to symptom overlap with other conditions and lack of awareness. Genetic testing confirms the diagnosis by identifying mutations associated with the syndrome.
Are there any new treatments or clinical trials available?
Research is ongoing, with gene therapy and novel pharmacological approaches being explored. CRISPR-Cas9 and other gene-editing technologies show promise in treating hereditary diseases. ClinicalTrials.gov is a resource for finding current trials, and patients should discuss potential participation with their doctors. Questions to ask include eligibility, potential benefits, and risks of trial participation. New treatments may take years to become widely available, so ongoing management with current therapies is essential.
How does this condition affect daily life and activities?
Mobility can be significantly impacted due to tendon contractures and muscle weakness, affecting self-care abilities. Educational accommodations may be necessary for children with the condition. Social and emotional challenges include coping with chronic illness and potential isolation. The condition can place a significant burden on families, requiring adaptations and support. Supportive therapies, assistive devices, and community resources can help manage daily life challenges.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Pulmonary alveolar proteinosis.
Trapnell BC, Nakata K, Bonella F et al. · Nat Rev Dis Primers · 2019 · PMID: 30846703
- 2.Treatment Approaches for Alport Syndrome.
Rheault MN · J Am Soc Nephrol · 2026 · PMID: 40938675
- 3.CRISPR-Cas9 for treating hereditary diseases.
Mani I · Prog Mol Biol Transl Sci · 2021 · PMID: 34127193
- 4.Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders.
Wilson SE · J Ocul Pharmacol Ther · 2023 · PMID: 36877777
- 5.Emerging concepts and treatments in autoinflammatory interferonopathies and monogenic systemic lupus erythematosus.
Goldbach-Mansky R, Alehashemi S, de Jesus AA · Nat Rev Rheumatol · 2025 · PMID: 39623155
- 6.NKX2-1-Related Disorders.
Adam MP, Bick S, Mirzaa GM et al. · Unknown Journal · 1993 · PMID: 24555207
- 7.Activation of Stimulator of IFN Genes (STING) Causes Proteinuria and Contributes to Glomerular Diseases.
Mitrofanova A, Fontanella A, Tolerico M et al. · J Am Soc Nephrol · 2022 · PMID: 36198430
- 8.Gilbert syndrome.
Fretzayas A, Moustaki M, Liapi O et al. · Eur J Pediatr · 2012 · PMID: 22160004
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-06-13